166 related articles for article (PubMed ID: 37491871)
1. Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis.
Lou Q; Gong J; Ye B; Yu R; Bu S; Li Y; Zhu B; Shao L
Ren Fail; 2023 Dec; 45(1):2238823. PubMed ID: 37491871
[TBL] [Abstract][Full Text] [Related]
2. Risk of acute kidney injury by initiation of non-steroidal anti-inflammatory drugs in hospitalised patients treated with diuretics and renin-angiotensin-aldosterone system inhibitors.
Bories M; Bacle A; Gilardi H; Le Corre P
Eur J Hosp Pharm; 2022 Nov; 29(6):359-361. PubMed ID: 33478983
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
5. Time until onset of acute kidney injury by combination therapy with "Triple Whammy" drugs obtained from Japanese Adverse Drug Event Report database.
Kunitsu Y; Hira D; Morikochi A; Ueda T; Isono T; Morita SY; Terada T
PLoS One; 2022; 17(2):e0263682. PubMed ID: 35139129
[TBL] [Abstract][Full Text] [Related]
6. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.
Dreischulte T; Morales DR; Bell S; Guthrie B
Kidney Int; 2015 Aug; 88(2):396-403. PubMed ID: 25874600
[TBL] [Abstract][Full Text] [Related]
7. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
8. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
10. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
Cortazar FB; Kibbelaar ZA; Glezerman IG; Abudayyeh A; Mamlouk O; Motwani SS; Murakami N; Herrmann SM; Manohar S; Shirali AC; Kitchlu A; Shirazian S; Assal A; Vijayan A; Renaghan AD; Ortiz-Melo DI; Rangarajan S; Malik AB; Hogan JJ; Dinh AR; Shin DS; Marrone KA; Mithani Z; Johnson DB; Hosseini A; Uprety D; Sharma S; Gupta S; Reynolds KL; Sise ME; Leaf DE
J Am Soc Nephrol; 2020 Feb; 31(2):435-446. PubMed ID: 31896554
[TBL] [Abstract][Full Text] [Related]
11. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
[TBL] [Abstract][Full Text] [Related]
14. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration.
Lee EJ; Jang HN; Cho HS; Bae E; Lee TW; Chang SH; Park DJ
Ren Fail; 2018 Nov; 40(1):687-692. PubMed ID: 30741619
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
16. Diuretics associated acute kidney injury: clinical and pathological analysis.
Wu X; Zhang W; Ren H; Chen X; Xie J; Chen N
Ren Fail; 2014 Aug; 36(7):1051-5. PubMed ID: 24940940
[TBL] [Abstract][Full Text] [Related]
17. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
[TBL] [Abstract][Full Text] [Related]
18. Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.
Zahid U; Ramachandran P; Spitalewitz S; Alasadi L; Chakraborti A; Azhar M; Mikhalina G; Sherazi A; Narh JT; Khattar P; Bedi P
Am J Nephrol; 2020; 51(10):786-796. PubMed ID: 33011717
[TBL] [Abstract][Full Text] [Related]
19. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
20. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: "The Triple Whammy".
Camin RM; Cols M; Chevarria JL; Osuna RG; Carreras M; Lisbona JM; Coderch J
Nefrologia; 2015; 35(2):197-206. PubMed ID: 26300514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
